<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1009234160
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2019
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ESIDREX TAB. 25 MG
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        HYDROCHLOROTHIAZIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        25
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        17.25
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Siegfried Barbera, S.L" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Siegfried Barbera, S.L
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 360]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Farouk, Maamoun Tamer & CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Laboratoires Juvisé Pharmaceuticals
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C03AA03
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Composition</strong></p><p><em>Active substance</em>: Hydrochlorothiazide</p><p><em>Excipients:</em> Tableting excipients</p><p><strong>Pharmaceutical form and quantity of active substance per unit</strong></p><p>Scored tablets of 25 mg</p><p><strong>Indications / Potential uses</strong></p><p><em>Hypertension:</em> As monotherapy and in combination with other antihypertensives. (e.g. betablockers, vasodilators, calcium antagonists, ACE inhibitors, reserpine).</p><p><em>Heart failure.</em></p><p><em>Oedema </em>due to heart failure or mild to moderate kidney or liver failure.</p><p><em>Nephrogenic diabetes insipidus</em>.</p><p><em>Idiopathic hypercalciuria and prevention of recurrent calcium oxalate calculi.</em></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Anuria, severe renal and hepatic failure.</p><p>Hypersensitivity to hydrochlorothiazide and other sulphonamide derivatives. Refractory hypokalaemia, hyponatraemia, and hypercalcaemia.</p><p>Symptomatic hypercalcaemia (history of gout or uric acid calculi).</p><p>Hypertension during pregnancy.</p><p>Creatinine clearance below 30ml/minute.</p><p>Condition associated with increased potassium loss, e.g. salt-losing nephropathies and prerenal (cardiogenic) kidney dysfunction.</p><p><strong>Warnings and Precautions</strong></p><p>Esidrex should be used with caution in patients with renal disease or impaired liver function (see contraindications and Dosage and Administration).</p><p><strong>Electrolytes</strong></p><p>Like all thiazide diuretics, Esidrex causes dose-dependent kaliuresis. During 6 months of treatment with 12.5 mg daily, serum potassium concentrations decrease by an average of 0.36 mmol/litre. Serum potassium concentrations should be checked at the beginning of long-term therapy and again 3-4 weeks later.</p><p>Thereafter they should be measured every 4-6 months, unless the potassium balance is disturbed by other factors, such as vomiting, diarrhoea, change in renal function etc.</p><p>Concomitant administration of an oral potassium salt (e.g. KCI) in an individually adapted dosage may be considered in patients receiving digitalis or showing signs of coronary heart disease, unless they are also receiving an ACE inhibitor.</p><p>The same applies to patients receiving high doses of beta-adrenergic agonists and in all patients in whom serum potassium concentrations are below 3.0 mmol/litre. If oral potassium preparations are not tolerated, Esidrex can be combined with a potassium-sparing diuretic.</p><p>Whenever combination treatment is given, the patient should be closely monitored to ensure maintenance or normalization of the potassium balance. If hypokalaemia is accompanied by clinical signs of potassium depletion (e.g. muscle weakness, paresis or ECG changes), Esidrex should be discontinued</p><p>Patients who are also receiving an ACE inhibitor should not be given Esidrex in combination with a potassium salt or a potassium- sparing diuretic.</p><p>Hyponatraemia accompanied by neurological symptoms (nausea, weakness, progressive disorientation, apathy) has been observed in isolated cases.</p><p>Monitoring of serum electrolytes is particularly called for in elderly patients, patients with ascites due to liver cirrhosis, and patients with oedema due to nephrotic syndrome. In the case of oedema due to nephrotic syndrome, Esidrex should not be used unless the patient is normokalaemic and there are no signs of volume depletion or severe hypoalbuminaemia; if it is used, close surveillance is indicated.</p><p><strong>&nbsp;</strong></p><p><strong>Metabolic effects</strong></p><p>Like other diuretics, Esidrex can raise serum uric acid levels, but attacks of gout are seldom seen during prolonged treatment.</p><p>As with all thiazide diuretics, glucose tolerance may change during long-term treatment with Esidrex; this effect is less pronounced with lower doses.</p><p>Thiazides rarely cause frank diabetes mellitus, especially if there are no predisposing factors.</p><p>Slight and partly reversible increases in plasma concentrations of total cholesterol, triglycerides, or low-density-lipoprotein cholesterol have been observed during long-term treatment with thiazides and thiazide-like diuretics. The clinical relevance of these findings is disputed. Esidrex should not be used as a first-line drug for long-term treatment of patients with overt diabetes mellitus or patients receiving treatment for hypercholesterolaemia (diet alone or diet combined with drug therapy).</p><p>Thiazides reduce calcium excretion. During long-term treatment with thiazides, pathological changes in the parathyroid gland accompanied by hypercalcaemia and hypophosphataemia have been observed in a few patients. If hypercalcaemia occurs, further diagnostic clarification is necessary.</p><p>The complications that usually arise with hyperparathyroidism, e.g. nephrolithiasis, bone resorption and peptic ulcer, have not been seen.</p><p>&nbsp;</p><p><strong>Efficacy, dosage and renal function</strong></p><p>Patients with renal failure: It is recommended that the dosage be halved in patients with kidney failure (creatinine clearance of 30 &ndash;70 ml/ minute).</p><p>Thiazide diuretics, including Esidrex, lose their diuretic effect when creatinine clearance is below 30 ml/minute (or when serum creatinine levels are above 2.5 mg/100 ml). In such cases a loop diuretic is indicated.</p><p>&nbsp;</p><p><strong>Non-melanoma skin cancer </strong></p><p>An increased risk of non-melanoma skin cancer (NMSC) [basal cell carcinoma (BCC) and squamous cell carcinoma (SCC)] with increasing cumulative dose of hydrochlorothiazide (HCTZ) exposure has been observed in two epidemiological studies based on the Danish National Cancer Registry. Photosensitizing actions of HCTZ could act as a possible mechanism for NMSC. Patients taking HCTZ should be informed of the risk of NMSC and advised to regularly check their skin for any new lesions and promptly report any suspicious skin lesions. Possible preventive measures such as limited exposure to sunlight and UV rays and, in case of exposure, adequate protection should be advised to the patients in order to minimize the risk of skin cancer. Suspicious skin lesions should&nbsp; be promptly examined potentially including histological examinations of biopsies. The use of&nbsp; HCTZ&nbsp; may also need to be reconsidered in patients who have experienced previous NMSC (see &laquo;Adverse effects&raquo;).</p><p>&nbsp;</p><p><strong>Choroidal effusion, acute myopia and secondary angle- closure glaucoma:</strong></p><p>Sulfonamide or sulfonamide derivative drugs can cause an idiosyncratic reaction resulting in choroidal effusion with visual field defect, transient myopia and acute angle-closure glaucoma. Symptoms include acute onset of decreased visual acuity or ocular pain and typically occur within hours to weeks of drug initiation. Untreated acute angle-closure glaucoma can lead to permanent vision loss. The primary treatment is to discontinue drug intake as rapidly as possible. Prompt medical or surgical treatments may need to be considered if the intraocular pressure remains uncontrolled. Risk factors for developing acute angle- closure glaucoma may include a history of sulfonamide or penicillin allergy.</p><p>&nbsp;</p><p><strong>Other</strong></p><p>Substances that increase plasma renin activity (i.e. diuretics) potentiate the antihypertensive effect of ACE inhibitors. The dosage should therefore be carefully adjusted if an ACE inhibitor is given in addition to treatment with a diuretic.</p><p>Lupus erythematosus may be activated during treatment with thiazides.</p><p>&nbsp;</p><p><strong>Interactions</strong></p><p>Since diuretics can raise blood lithium levels, these must be monitored in patients receiving lithium during treatment with Esidrex. If lithium has induced polyuria, diuretics may have a paradoxical antidiuretic effect.</p><p>Thiazides potentiate the effect of curare derivatives and antihypertensive drugs (e.g. guanethidine, methyldopa, beta-blockers, vasodilators, calcium antagonists and ACE inhibitors).</p><p>The hypokalaemic effect of diuretics may be potentiated by corticosteroids, ACTH, amphotericin and carbenoxolone (not approved in Switzerland).</p><p>It may be necessary to adapt the dosage of insulin and oral antidiabetic agents.</p><p>Hypokalaemia or hypomagnesaemia, which can occur as adverse effects of thiazide treatment, may promote the onset of digitalis-induced cardiac arrhythmias (see Warnings and Precautions).</p><p>Concomitant administration of certain non-steroidal anti-inflammatory agents (e.g. indometacin) may reduce the diuretic and antihypertensive effects of diuretics. Isolated cases of deterioration in renal function have been reported in predisposed patients.</p><p>&nbsp;</p><p>Allopurinol</p><p>Concomitant treatment with thiazide diuretics may increase the frequency of hypersensitivity reactions to allopurinol.</p><p>Amantadine</p><p>Concomitant use of thiazide diuretics may increase the risk of adverse effects caused by amantadine.</p><p>Antineoplastic agents (e.g. cyclophosphamide, methotrexate)</p><p>Concomitant use of thiazide diuretics with antineoplastic agents may reduce renal excretion of the cytotoxic agents and potentiate their myelosuppressive effects.</p><p>Anticholinergic agents (e.g. atropine, biperiden)The bioavailability of thiazide-like diuretics may be increased by anticholinergic agents, apparently owing to reduced gastrointestinal motility and slower gastric emptying.</p><p>Colestyramine</p><p>The absorption of thiazide diuretics is decreased by colestyramine, which means that their pharmacological effect is likely to be reduced during co-medication.</p><p>Vitamin D</p><p>The increase in serum calcium is potentiated when thiazide diuretics, which may lower urinary calcium excretion, are administered together with vitamin D.</p><p>Ciclosporin</p><p>Concomitant treatment with ciclosporin may increase the risk of hyperuricaemia and gout-like complications.</p><p>Calcium salts</p><p>Concomitant treatment with calcium salts may lead to hypercalcaemia due to the increase in tubular calcium reabsorption.</p><p>Diazoxide</p><p>Thiazide diuretics can potentiate the hyperglycaemic effect of diazoxide.</p><p>Methyldopa</p><p>There have been reports in the literature of haemolytic anaemia occurring during concomitant treatment with hydrochlorothiazide and methyldopa.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Dosage and Administration</strong></p><p>The dosage depends on the clinical picture and the patient&rsquo;s response. Where a single daily dose is prescripted, this is best taken in the morning with breakfast.</p><p>In the case of long‑term therapy, the lowest dose compatible with maintenance of optimum effect should be given, particularly in elderly patients.</p><p><strong>Hypertension</strong></p><p>Adults: The initial dosage is usually 25-50 mg daily, taken in the morning or in two divided doses.</p><p>For long-term treatment 12.5&ndash;25 mg every morning is often sufficient. If blood pressure reduction is not adequate, co-medication with another antihypertensive (e.g. betablockers, vasodilators, calcium antagonists, ACE inhibitors, reserpine) is recommended. This way the dosage of each substance can often be kept lower.</p><p><strong>Heart failure and oedema</strong></p><p>Adults: The initial dose is 25‑75 mg daily, given in 1‑2 doses. In isolated cases this can be increased, but doses exceeding 100 mg rarely result in an additional increase in efficacy. If the effect is inadequate, positive inotropic substances and vasodilatators should be used. Once the patient has begun to respond satisfactorily, 25 mg daily &ndash; or possibly every other day &ndash; is usually adequate for maintenance therapy.</p><p>The mean dosage in children is usually up to 2 mg/kg daily, depending on the clinical picture.</p><p><strong>Nephrogenic diabetes insipidus</strong></p><p>Adults: The initial dose is 100 mg daily, given in 2‑4 single doses. Later the dosage may be reducted. Experience in children is limited to isolated cases and dosage should therefore be determined on an individual basis in hospital.</p><p><strong>Idiopathic hypercalciuria and prevention of recurrent calcium oxalate calculi</strong></p><p>Adults: 25‑50 mg twice daily.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Frequency </strong></p><p>&ldquo;Very common&rdquo; (&gt;1/10), &ldquo;common&rdquo; (&gt;1/100&nbsp;&nbsp; to&nbsp;&nbsp; &lt;1/10), &ldquo;uncommon&rdquo; (&gt;1/1000 to &lt;1/100), &ldquo;rare&rdquo; (&gt;1/10 000 to &lt;1/1000), &ldquo;very rare&rdquo; (&lt;1/10 000).</p><p><strong>Blood</strong></p><p>Rare: Thrombocytopenia, sometimes with purpura.</p><p>Very rare: Leucopenia, agranulocytosis, bone-marrow depression, haemolytic anaemia.</p><p><strong>Immune system</strong></p><p>Very rare: Hypersensitivity reactions.</p><p><strong>Electrolyte and metabolic disturbances</strong></p><p>Common:&nbsp;&nbsp; Hypokalaemia,&nbsp;&nbsp; especially&nbsp;&nbsp; with&nbsp;&nbsp; higher&nbsp;&nbsp; doses; increase in blood lipid levels.</p><p>Uncommon:&nbsp;&nbsp; Hyponatraemia,&nbsp;&nbsp; hypomagnesaemia&nbsp;&nbsp; and hyperuricaemia.</p><p>Rare: Hypercalcaemia, hyperglycaemia, glycosuria, deterioration of diabetic metabolic status.</p><p>Very rare: Hypochloraemic alkalosis.</p><p><strong>Nervous system</strong></p><p>Rare:&nbsp;&nbsp; Headache,&nbsp;&nbsp; dizziness&nbsp;&nbsp; or&nbsp;&nbsp; light-headedness,&nbsp;&nbsp; sleep disturbances, depression and paraesthesias.</p><p><strong>Eye disorders</strong></p><p>Disturbances of vision, particularly during the first few weeks of treatment.</p><p>Unknown: Chloroidal effusion</p><p><strong>Cardiovascular system</strong></p><p>Uncommon:&nbsp;&nbsp;&nbsp;&nbsp; Orthostatic&nbsp;&nbsp;&nbsp;&nbsp; hypotension,&nbsp;&nbsp; &nbsp;&nbsp;which&nbsp;&nbsp;&nbsp;&nbsp; may&nbsp; be&nbsp; aggravated&nbsp; by&nbsp; alcohol,&nbsp; anaesthetics&nbsp; or&nbsp; sedatives.</p><p>Rare: Cardiac arrhythmias.</p><p><strong>Respiratory tract</strong></p><p>Very&nbsp;&nbsp;&nbsp;&nbsp; rare:&nbsp;&nbsp;&nbsp;&nbsp; Respiratory&nbsp;&nbsp;&nbsp;&nbsp; symptoms&nbsp;&nbsp;&nbsp;&nbsp; including&nbsp;&nbsp;&nbsp;&nbsp; pneumonitis and pulmonary oedema.</p><p><strong>Gastrointestinal tract</strong></p><p>Uncommon:&nbsp;&nbsp;&nbsp; Appetite&nbsp;&nbsp;&nbsp; loss,&nbsp;&nbsp;&nbsp; mild&nbsp;&nbsp;&nbsp; nausea&nbsp;&nbsp;&nbsp; and&nbsp;&nbsp;&nbsp; vomiting.</p><p>Rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abdominal&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; symptoms,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; constipation,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhoea and gastrointestinal symptoms.</p><p>Very rare: Pancreatitis.</p><p><strong>Liver</strong></p><p>Rare: Intrahepatic cholestasis or jaundice.</p><p><strong>Skin</strong></p><p>Uncommon:&nbsp;&nbsp; Urticaria&nbsp;&nbsp; and&nbsp;&nbsp; other&nbsp;&nbsp; types&nbsp;&nbsp; of&nbsp;&nbsp; rash,&nbsp;&nbsp; including&nbsp;&nbsp; erythema,&nbsp;&nbsp; sometimes&nbsp;&nbsp; associated&nbsp;&nbsp; with&nbsp;&nbsp; pruritus.</p><p>Rare: Photosensitivity.</p><p>Very&nbsp; rare:&nbsp; Necrotizing&nbsp; vasculitis,&nbsp; toxic&nbsp; epidermal&nbsp; necrolysis,&nbsp;&nbsp;&nbsp;&nbsp; lupus-erythematosus-like&nbsp;&nbsp;&nbsp;&nbsp; reactions,&nbsp;&nbsp;&nbsp;&nbsp; reactivation of cutaneous lupus erythematosus.</p><p><strong>Reproductive system</strong></p><p>Uncommon: Impotence.</p><p>&nbsp;</p><p><strong>Post-marketing adverse effects</strong></p><p>The following adverse effects have been identified based on post marketing experience.</p><p>Because these effects are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequencies.</p><p>Frequency not known:</p><p>non-melanoma skin cancer (Basal&nbsp; cell&nbsp; carcinoma&nbsp; and Squamous cell carcinoma).</p><p>&nbsp;</p><p><strong>Description of selected adverse reactions</strong></p><p><u>Non-melanoma&nbsp; skin&nbsp; cancer</u>:&nbsp; Based&nbsp; on&nbsp; available&nbsp; data&nbsp;&nbsp; from&nbsp;&nbsp; epidemiological&nbsp;&nbsp; studies,&nbsp;&nbsp; cumulative&nbsp;&nbsp; dose-dependent&nbsp;&nbsp; association&nbsp;&nbsp; between&nbsp;&nbsp; HCTZ&nbsp;&nbsp; and&nbsp;&nbsp; NMSC&nbsp; has&nbsp; been&nbsp; observed&nbsp; (see&nbsp; sections&nbsp; &laquo;Warning&nbsp; and precautions&raquo; and &laquo;Properties/Actions&raquo;).</p><p><u>Choroidal effusion, acute myopia and secondary angle- closure glaucoma</u>: Sulfonamide or sulfonamide derivative drugs can cause an idiosyncratic reaction resulting in choroidal effusion with visual field defect, transient myopia and acute angle-closure glaucoma. Symptoms include acute onset of decreased visual acuity or ocular pain and typically occur within hours to weeks of drug initiation. Untreated acute angle-closure glaucoma can lead to permanent vision loss. The primary treatment is to discontinue drug intake as rapidly as possible. Prompt medical or surgical treatments may need to be considered if the intraocular pressure remains uncontrolled. Risk factors for developing acute angle- closure glaucoma may include a history of sulfonamide or penicillin allergy.</p><p><u>&nbsp;</u></p><p><u>Please report adverse drug events to:</u></p><p>The National Pharmacovigilance Centre (NPC): Fax: +966-11-205-7662</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Store in the original package away from moisture.</p><p>Store in the original package away from light.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Composition</strong></p><p><em>Active substance</em>: Hydrochlorothiazide</p><p><em>Excipients:</em> Tableting excipients</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Scored tablet.
The tablet can be divided into two equal half-doses.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>MAH: LABORATOIRES JUVISE PHARMACEUTICALS</p><p>149 BOULEVARD BATAILLE DE STALINGRAD</p><p>69100 VILLEURBANNE</p><p>Manufacturer:&nbsp;</p><p>Cenexi</p><p>Fontenay-sous-Bois, France</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                03/2021
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>التركيب</strong></p><p dir="RTL"><em>المادة الفعالة</em>: هيدروكلوروثيازيد</p><p dir="RTL"><em>السواغ</em>: سواغ لعمل أقراص</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الشكل الصيدلاني وكمية المادة الفعالة في كل وحدة</strong></p><p dir="RTL">أقراص محززة بها 25 مجم</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>دواعي الاستعمال/ الاستخدامات الممكنة</strong></p><p dir="RTL"><em>ارتفاع ضغط الدم</em> : كعلاج أحادي وبالاشتراك مع الأدوية</p><p dir="RTL">الأخرى الخافضة لضغط الدم المرتفع (مثل حاصرات البيتا،</p><p dir="RTL">موسعات الأوعية، مضادات الكالسيوم، مثبطات الإنزيم المحول</p><p dir="RTL">للانجيوتنسين ACE، ريزربين).</p><p dir="RTL"><em>الفشل القلبي.</em></p><p dir="RTL"><em>الوذمة</em> الناتجة عن الفشل القلبي ،&nbsp; أو الفشل الكلوي الطفيف إلى</p><p dir="RTL">المتوسط أو الفشل الكبدي.</p><p dir="RTL"><em>البوالة التفهة ذات المنشأ الكلوي.</em></p><p dir="RTL"><em>الزيادة ذاتية المنشأ لإفراز الكالسيوم في البول ،&nbsp; والوقاية من</em></p><p dir="RTL"><em>حصوات اوكسالات الكالسيوم المتكررة</em><em>.</em></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الجرعة/ طريقة الاستعمال</strong></p><p dir="RTL">تعتمد الجرعة على الصورة الإكلينيكية وعلى استجابة المريض.</p><p dir="RTL">عندما تكون الجرعة الموصوفة مرة واحدة يوميا، يُفضل إعطاؤها</p><p dir="RTL">في الصباح مع وجبة الإفطار.</p><p dir="RTL">في حالة العلاج طويل الأمد، يجب إعطاء أدنى جرعة متوافقة</p><p dir="RTL">مع التأثير الأمثل، ولا سيما في المرضى المسنين.</p><p dir="RTL"><strong>ارتفاع ضغط الدم</strong></p><p dir="RTL">البالغون: الجرعة الابتدائية هي عادةً 25-50 مجم يوميا، تؤخذ</p><p dir="RTL">في الصباح أو تُقسم إلى جرعتين. للعلاج طويل الأمد، يكفي عادةً</p><p dir="RTL">إعطاء 12.5-25 مجم كل صباح. إذا لم يتحقق الخفض الكافي</p><p dir="RTL">لضغط الدم المرتفع (مثل أحد حاصرات البيتا، أحد موسعات</p><p dir="RTL">الاوعية، أحد مضادات الكالسيوم، أحد مثبطات الإنزيم المحول</p><p dir="RTL">ريزربين)، ACE للإنجيوتنسين</p><p dir="RTL">بهذه الطريقة يمكن الحفاظ على جرعة كل مادة عند مستوى أدنى.</p><p dir="RTL"><strong>الفشل القلبي والوذمة</strong></p><p dir="RTL">البالغلون: الجرعة الابتدائية هي 25-75 مجم يوما، تُعطى في</p><p dir="RTL">شكل 1-2 جرعة. في حالات منعزلة، يمكن زيادة هذه الجرعة،</p><p dir="RTL">غير أن الجرعات التي تتجاوز 100 مجم نادرا ما تؤدي إلى زيادة</p><p dir="RTL">إضافية في الفاعلية. إذا كان التأثير غير كافِ، يجب استخدام</p><p dir="RTL">مواد ذات تأثير عضلي موجب</p><p dir="RTL">وموسعات للأوعية. بمجرد أن يبدأ المريض في الاستجابة</p><p dir="RTL">بشكل مناسب، يكفي عادة استخدام 25 مجم / يوميا &ndash; أو ربما</p><p dir="RTL">كل يومين -كعلاج استمراري. متوسط الجرعة في الأطفال</p><p dir="RTL">تصل عادةً إلى 2 مجم / كجم / يوميا، وفقا للصورة الإكلينيكية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>البوالة التفهة ذات المنشأ الكلوي</strong></p><p dir="RTL">البالغون: الجرعة الابتدائية هي 100 مجم يوميا، تُعطى على هيئة</p><p dir="RTL">2-4- جرعات مًفردة. ويمكن فيما بعد خفض الجرعة. تقتصر</p><p dir="RTL">الخبرة في الأطفال على حالات منعزلة، وبالتالي يجب تحديد</p><p dir="RTL">الجرعة على أساس فردي في المستشفى.</p><p dir="RTL"><strong>الزيادة ذاتية المنشأ الإفراز الكالسيوم في البول، والوقاية</strong></p><p dir="RTL"><strong>من حصوات أوكسالات الكالسيوم المتكررة</strong></p><p dir="RTL">البالغون: 25-50 مجم مرتين يومياً.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>موانع الاستعمال</strong></p><p dir="RTL">انقطاع البول، الفشل الكلوي والكبدي الشديد. الحساسية المفرطة</p><p dir="RTL">تجاه هيدروكلوروثيازيد وسائر مشتقات السلفوناميد. الحالات</p><p dir="RTL">المستعصية من نقص بوتاسيوم الدم ، ونقص صوديوم الدم ،</p><p dir="RTL">وزيادة كالسيوم الدم. زيادة حمض البوليك في الدم المصحوب</p><p dir="RTL">بأعراض (تاريخ عن نقرس أو حصوات حمض البوليك).</p><p dir="RTL">ارتفاع ضغط الدم أثناء الحمل.</p><p dir="RTL">تصفية الكرياتينين أقل من ٣٠ ملليلتر / دقيقة. الأحوال المصحوبة</p><p dir="RTL">بزيادة فقدان البوتاسيوم ، مثل الأمراض الكلوية الفاقدة للملح</p><p dir="RTL">وخلل وظيفة الكلي قبل الكلوي (قلبي المنشأ).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التحذيرات والاحتياطات</strong></p><p dir="RTL">يجب استعمال إزيدركس بحذر في المرضى الذين لديهم مرضى</p><p dir="RTL">&nbsp;كلوي أو ضعف بالوظيفة الكبدية (انظر <strong>موانع الاستعمال</strong><strong> </strong></p><p dir="RTL"><strong>والجرعة وطريقة الاستعمال</strong>).</p><p dir="RTL"><strong>الإلكترونيات</strong></p><p dir="RTL">شأنه شأن جميع مدرات البول الثيازيدية، بسبب إزيدركس</p><p dir="RTL">بيلة بوتاسية معتمدة على الجرعة. خلال&nbsp; ٦ شهور من العلاج</p><p dir="RTL">بالجرعة &nbsp;٥ ر٢ ١ &nbsp;مجم يوميا، تنخفض تركيزات البوتاسيوم&nbsp; في</p><p dir="RTL">المصل بمتوسط ٣٦ ر٠&nbsp; مللي مول / لتر. يجب قياس تركيزات</p><p dir="RTL">&nbsp;البوتاسيومفي المصل عند بدء العلاج طويل الأمد ثم مرة أخرى</p><p dir="RTL">بعد 4-3 أسابيع بعد ذلك يجب قياسها كل 4-6 شهور، ما لم</p><p dir="RTL">يختل توازن البوتاسيوم بسبب عوامل أخرى، مثل القيء، والإسهال،</p><p dir="RTL">وتغير الوظيفة الكلوية، إلخ.</p><p dir="RTL">يمكن التفكير في الإعطاء المتزامن لملح بوتاسيوم بالفم (مثل</p><p dir="RTL">كلوريد البوتاسيوم) بجرعة مضبوطة بشكل فردي، في المرضى</p><p dir="RTL">الذين يتلقون&nbsp; ديجيتاليس أو يُظهرون علامات المرض القلبي</p><p dir="RTL">التاجي، ما لم يمونوا يتلقون أيضًا أحد مثبطات الإنزيم المحول</p><p dir="RTL">للأننجيوتنسين (ACE) . وينطبق ذلك أيضًا على المرضى الذين</p><p dir="RTL">يتلقون جرعات عالية من مشددات بيتا الأدرينالية وفي جميع</p><p dir="RTL">المرضى الذين لديهم تركيزات البوتاسيوم في المصل أقل من</p><p dir="RTL">&nbsp;٣ ر ٠ مللي مول/ لتر. في حالة عدم تحمل مستحضرات</p><p dir="RTL">البوتاسيوم التي تُؤخد بالفم، يمكن الجمع بين إزيدركس وبين</p><p dir="RTL">&nbsp;أحد مدرات البول المقتصدة للبوتاسيوم.</p><p dir="RTL">عند إعطاء علاج مُشترك، يجب مراقبة المريض بدقة لضمان</p><p dir="RTL">الحفاظ على توازن البوتاسيوم أو تصحيحه إذا كان نقص</p><p dir="RTL">بوتاسيوم الدم مصحوباً بعلامات إكلينيكية تدل على نفاد</p><p dir="RTL">البوتاسيوم (مثل الضعف العضلي، أو&nbsp; الخزل، أو حدوث تغيرات</p><p dir="RTL">في رسم القلب الكهربي ECG)، يوقف استعمال إزيدركس.</p><p dir="RTL">المرضى الذين يتلقون أيضاً أحد مثبطات الإنزيم المحول</p><p dir="RTL">للأنجيتنيبن &nbsp;ACE ، لا ينبغي أن يتلقوا إزيدركس، بالاشتراك مع</p><p dir="RTL">أحد أملاح البوتاسيوم أو أحد مدرات البول المقتصدة للبوتاسيوم.</p><p dir="RTL">شوهد في حالات منعزلة نقص في صوديوم الدم مصحوبا</p><p dir="RTL">بأعراض عصبية (غثيان، ضعف، شرود متزايد، خمول). يُنصح</p><p dir="RTL">بمراقبة إلكتروليتات المصل بصفة خاصة في المرضى المسنين،</p><p dir="RTL">والمرضى الذين لديهم استسقاء ناتج عن تليف الكبد، والمرضى</p><p dir="RTL">الذين لديهم وذمة ناتجة عن المتلازمة الكلائية. لا ينبغي استعمال إزدركس إلا إذا</p><p dir="RTL">كان بوتاسيوم الدم طبيعيا لدى المريض، ولم</p><p dir="RTL">تكن هناك علامات تدل على نفاد الحجم أو الانخفاض الشديد</p><p dir="RTL">لألبومين الدم؛ وإذا تم استعماله، يوصى بالإشراف الدقيق.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الاثار الأيضية</strong></p><p dir="RTL">شأنه شأن سائر مدرات البول، قد يؤدي إزيدركس إلى رفع</p><p dir="RTL">مستويات حمض البوليك في المصل، غير أنه قد شوهدت بصفة</p><p dir="RTL">نادرة نوبات نقرس أثناء العلاج المطوًل.</p><p dir="RTL">مثلما يحدث مع جميع مدرات البول الثيازيدية، قد تتغير القدرة</p><p dir="RTL">على تحمل الجلوكوز أثناء العلاج طويل الأمد بإزيدرك؛ ويكون</p><p dir="RTL">هذا الأثر أقل وضوحا مع الجرعات الأدنى. نادرا ما تؤدي</p><p dir="RTL">الثيازيدات إلى حدوث مرض السكر بشكل صريح، ولا سيما</p><p dir="RTL">في عدم وجود عوامل مؤهبة.</p><p dir="RTL">شوهدت زيادات طفيفة وفابلة جزئياً للعكس في تركيزات</p><p dir="RTL">الكولسترول الغجمالي، والجلسريدات الثلاثية، وكولسترول</p><p dir="RTL">البروتين الدهني المنخفض الكثافة في البلازما، أثناء العلاج</p><p dir="RTL">طويل الأمد بمدرات البول الثيازيدية وشبه الثيازيدية. هناك</p><p dir="RTL">جدل بشأن الدلالة الإكلينيكية لهذه النتائج.</p><p dir="RTL">لا ينيبغي استعمال إزيردكس كدواء من الصف الأول للعلاج طويل</p><p dir="RTL">الأمد في المرضى الذين لديهم مرض السكر بشكل صريح، أو</p><p dir="RTL">المرضى الذين يتلقون علاجا لارتفاع الكولسترول في الدم</p><p dir="RTL">(نظام غذائي فقط أو نظام غذائي بالاشتراك مع علاج دوائي).</p><p dir="RTL">تؤدي الثيازيدات إلى خفض إخراج الكالسيوم. أثناء العلاج طويل</p><p dir="RTL">&nbsp;</p><p dir="RTL">الأمد بالثيازيدات، شوهدت في مرضى قليلين تغيرات مَرَضية</p><p dir="RTL">في الغدة المجاورة للدرقية، وكانت هذه التغيرات مصحوبة</p><p dir="RTL">بارتفاع الكالسيوم وانخفاض الفوسفات في الدم. في حالة</p><p dir="RTL">ارتفاع الكالسيوم في الدم، يلزم مزيد من الإيضاح التشخيصي.</p><p dir="RTL">لم تُشاهد المضاعفات التي تنشأ عادةً مع زيادة نشاط الغدة</p><p dir="RTL">المجاورة للدرقية، مثل الحصوات الكلوية، وارتشاف العظم،</p><p dir="RTL">والقرحة الهضمية.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>الفاعلية، والجرعة، والوظيفية الكلوية</strong></p><p dir="RTL">مرضى الفشل الكلوي: يوصى بإعطاء نصف الجرعة للمرضى</p><p dir="RTL">&nbsp;الذين لديهم فشل كلوي (تصفية الكرياتينين 30-70 ملليلتر /</p><p dir="RTL">دقيقة).</p><p dir="RTL">تفقد مدرات البول الثيازيدية، وتشمل إزيدركس، تأثيرها المدر</p><p dir="RTL"><strong>للبول عندما تكون تصفية الكرياتينين أقققل من ٣٠ ملليلتر /</strong></p><p dir="RTL"><strong>دقيقة (أو عندما تكون مستويات كرياتينين المصل أعلى من ٣</strong></p><p dir="RTL">ر٥ مجم / ١٠٠ مللبلتر). في مثل هذه الحالات يوصى باستعمال</p><p dir="RTL">أحد مدرات البول العروية</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>سرطان الجلد غير الميلانيني</strong></p><p dir="RTL">تلاحظ تزايد احتمالية التعرض للإصابة بسرطان الجلد غير الملانيني</p><p dir="RTL">(NMSC) ]سرطان الخلايا القاعدية (BCC) وسرطان الخلايا الحرشفية (SCC)</p><p dir="RTL">[ مع التعرض لجرعة تراكمية متزايدة من هيدروكلوروثيازيد (HCTZ) في</p><p dir="RTL">دراستين وبائيتين استنادً إلى السجل الوطني الدنماركي للسرطان. يمكن</p><p dir="RTL">لإجراءات التحسس للضوء لمادة HCTZ ان تعمل كآلية محتملة لسرطان</p><p dir="RTL">الجلد غير الميلانيني &nbsp;NMSC ..يجب إبلاغ المرضى الذين يتناولون HCTZ</p><p dir="RTL">بمخاطر سرطان الجلد الملانيني NMSC ونصحهم بالتحقق من</p><p dir="RTL">بشرتهم بانتظام لمعرفة أي إصابات جديدة والإبلاغ الفوري عن أي</p><p dir="RTL">إصابات جلدية مثيرة للشك. يجب توجيه المرضى لاتخاذ التدابير الوقائية</p><p dir="RTL">الممكنة مثل التعرض المحدود لأشعة الشمس والأشعة فوق البنفسجية ،</p><p dir="RTL">وفي حالة التعرض ، نصحهم بالحماية المناسبة من اجل تقليل مخاطر</p><p dir="RTL">الإصابة بسرطان الجلد إلى أدنى حد. يجب فحص الإصابات الجلدية المثيرة</p><p dir="RTL">للشك بسرعة. كما قد يلزم إعادة النظر بعين الاعتبار لاستخدام HCTZ</p><p dir="RTL">مع المرضى الذين عانوا من سرطان الجلد الملانيني NMSC في لسابق</p><p dir="RTL">(انظر &quot;التأثيرات الجانبيه&quot;).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>انصباب المشيمية وقصر النظر الحاد والزّرَق مغلق الزاوية</strong><strong> </strong><strong>الثانوي:</strong></p><p dir="RTL">يمكن أن يتسبب السلفوناميد أو العقاقير المشتقة منه في حدوث</p><p dir="RTL">تفاعلات دوائية تختلف من حالة للأخرى وتؤدي إلى انصباب</p><p dir="RTL">المشيمية مع خلل في المجال البصري، وقصر النظر المؤقت،</p><p dir="RTL">والزّرَق مغلق الزاوية الحاد؛ وتشمل الأعراض الغحساس الشديد</p><p dir="RTL">ببداية انخفاض حدة البصر أو الشعور بألم شديد في العين، وعادة</p><p dir="RTL">ما تحدث هذه الأعراض في فترة تتراوح من ساعات إلى أسابيع</p><p dir="RTL">من البدء في تناول الدواء، ويمكن أن يؤدي التقصير في علاج</p><p dir="RTL">الزّرَق مغلق الزاوية الحاد إلى فقدان البصر الدائم. ويمكن العلاج</p><p dir="RTL">الأساسي في التوقف عن تناول الدواء في أسرع وقت ممكن، وقد</p><p dir="RTL">يلزم الأمر التداوي بالعقاقير الطبية أو التدخل الجراحي فورًا إذا ما</p><p dir="RTL">استمر المريض يعاني من الشعور بضغط داخل العين. زمن</p><p dir="RTL">العوامل التي تؤدي إلى حدوث الزّرَق مغلق الزاوية الحاد أن يكون</p><p dir="RTL">المريض يعاني من قبل من حساسية تجاه السلفوناميد أو&nbsp; البنسلين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أخرى</strong></p><p dir="RTL">المواد التي تُزيد من نشاط رينين البلازما (أي مدرات للبول)</p><p dir="RTL">تدهم الأثر الخافض لضغط الدم المرتفع الذي تزاوله مثبطات</p><p dir="RTL">الغنزيم المحول للأنجيوتنسين (ACE). لذلك يجب ضبط الجرعة</p><p dir="RTL">بعناية عند إعطاء أحد مثبطات الإنزيم المحول للأنجيوتنسين</p><p dir="RTL">(ACE) بالإضافة إلى العلاج بمدر للبول. قد يحدث تنشيط للذأب</p><p dir="RTL">الحمامي أثناء العلاج بالثيازيدات.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>التآثرات</strong></p><p dir="RTL">حيث أن مدرات البول قد تؤدي إلى ارتفاع مستويات الليثيوم</p><p dir="RTL">في الدم ، يجب مراقبة هذه المستويات في</p><p dir="RTL">المرضى الذين يتلقون ليثيوم أثناء العلاج بإزيدركس إذا أدى</p><p dir="RTL">الليثيوم إلى حدوث بوال ، فإن مدرات البول قد تزاول مفعولا</p><p dir="RTL">تناقضيا مضادا لإدرار البول.</p><p dir="RTL">تدعم الثيازيدات تأثير مشتقات الكوراري والأدوية الخافضة</p><p dir="RTL">لضغط الدم المرتفع (مثل جوانيثيدين، ميثيل دوبا، حاصرات</p><p dir="RTL">البيتا، موسعات الأوعية، مضادات الكالسيوم ، ومثبطات الإنزيم</p><p dir="RTL">المحول للأنجيوتنسين ACE). قد يشتد أثر مدرات اللبول الخافض</p><p dir="RTL">لبوتاسيوم الدم بالكورتيكوستيرويدات، والهرمون المعذي لقشرة</p><p dir="RTL">الكظر (ACTH)، وأمفوتريسين، وكاربينوكسولون (غير مسموح</p><p dir="RTL">به في سويسرا).</p><p dir="RTL">قد يلزم تعديل جرعة الأنسولين والمواد المضادة لمرض السكر</p><p dir="RTL">التي تؤخذ بالفم.</p><p dir="RTL">قد يؤدي نقص بوتاسيوم الدم ونقص ماغنسيوم الدم ، اللذان قد</p><p dir="RTL">يحدثان كآثار مناوئة للعلاج بالثيازيد ، إلى حدوث اللانظميات</p><p dir="RTL">القلبية الناجمة عن الديجيتاليس (انظر <strong>التحذيرات والاحتياطات</strong>).</p><p dir="RTL">قد يؤدي الاستعمال المتزامن لبعض المواد غير الستيرويدية</p><p dir="RTL">المضادة للالتهاب&nbsp; (مثل إندوميتاسين) إلى تقليل الآثار المدرة</p><p dir="RTL">للبول والخافضة لضغط الدم المرتفع الذي تزاوله مدرات البول.</p><p dir="RTL">وقد وردت تقارير عن حدوث حالات منعزلة من تدهور الوظيفة</p><p dir="RTL">الكلوية في المرضى ذوي القابلية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ألوبيورينول</p><p dir="RTL">قد يؤدي العلاج المتزامن بمدرات البول الثيازيدية إلى زيادة</p><p dir="RTL">معدل تكرار تفاعلات الحساسية المفرطة تجاه ألوبيورينول.</p><p dir="RTL">أمانتادين</p><p dir="RTL">قد يؤدي الاستعمال المتزامن لمدرات البول الثيازيدية إلى زيادة</p><p dir="RTL">مخاطرة حدوث الآثار المناوئة الناتجة عن أمانتادين.</p><p dir="RTL">الأدوية المضادة للأورام (مثل سيكلوفوسفاميد ،</p><p dir="RTL">ميثوتريكسات)</p><p dir="RTL">قد يؤدي الاستعمال المتزامن لمدرات البول الثيازيدية مع الأدوية</p><p dir="RTL">المضادة للأورام إلى تقليل الإخراج الكلوي للمواد السامة للخلايا</p><p dir="RTL">تشديد آثارها الخامدة للنخاع العطمي.</p><p dir="RTL">الأدوية المضادة للفعل الكوليني (مثل أتروبين، بيبريدين)</p><p dir="RTL">قد يزداد التوافر الحيوي لمدرات البول شبه الثيازيدية بواسطة</p><p dir="RTL">المواد المضادة للفعل الموليني، ويبدو أن السبب</p><p dir="RTL">حركية القناة الهضمية وبطء تفريغ المعدة</p><p dir="RTL">كولستيرامين</p><p dir="RTL">يقل امتصاص مدرات البول الثيازيدية بواسطة كولستيرامين،</p><p dir="RTL">مما يعني أن أثرها الدوائي قد ينخفض</p><p dir="RTL">أثناء المداواة الُمُشتركة.</p><p dir="RTL">فيتامين د</p><p dir="RTL">تشتد الزيادة في كالسيوم المصل عند إعطاء مدرات البول</p><p dir="RTL">الثيازيدية، التي قد تخفض الإخراج البولي</p><p dir="RTL">للكالسيوم ، بالاشتراك مع فيتامين د:</p><p dir="RTL">سيكلوسبورين</p><p dir="RTL">قد يؤدي الاستعمال المرافق بسيكلوسبورين إلى زيادة</p><p dir="RTL">مخاطرة ارتفاع حمض البوليك في الدم وحدوث مضاعفات</p><p dir="RTL">شبيهة بالنقرس.</p><p dir="RTL">أملاح الكالسيوم</p><p dir="RTL">قد يؤدي العلاج المرافق بأملاح الكالسيوم إلى ارتفاع الكالسيوم</p><p dir="RTL">في الدم بسبب زيادة إعادة الامتصاص النبيبي للكالسيوم.</p><p dir="RTL">ديازوكسيد</p><p dir="RTL">قد تؤدي مدرات البول الثيازيدية إلى اشتداد الأثر الرافع للسكر</p><p dir="RTL">في الدم الناتج عن ديازوكسيد.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ميثيل دوبا</p><p dir="RTL">توجد تقارير في المواد المطبوعة عن حدوث أنيميا انحلالية أثناء</p><p dir="RTL">العلاج المتزامن بهيدروكلوروثيازيد وميثيل دوبا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والإرضاع</strong></p><p dir="RTL">يعبر هيدروكلوروثيازيد حاجز المشيمة. رغم أنه لم تُشاهَد أي</p><p dir="RTL">آثار سامة للتناسل في الدراسات على الحيوانات، إلا أنه يُشتبه</p><p dir="RTL">في الإنسان أن الاستعمال خلال النصف الثاني من الحمل قد</p><p dir="RTL">يسبب نقص الصفيحات في حديثي الولادة. لذلك لا ينبغي</p><p dir="RTL">استعمال إزيدركس أثناء الحمل ما لم تكن هناك ضرورة واضحة.</p><p dir="RTL">بالإضافة إلى ذلك ، فإن إزيدركس -شأنه شأن سائر مدرات</p><p dir="RTL">البول -قد يؤدي إلى نقص إرواء المشيمة. حيث أن هذه الأدوية</p><p dir="RTL">لا تمنع ولا تؤثر على مسار مقدمات الارتعاج أو EPH&nbsp; (وذمة-بيلة</p><p dir="RTL">بروتينية وارتفاع ضغط الدم) المصاحب لتسمم الحمل ، فلا</p><p dir="RTL">ينبغي استعمالها لعلاج ارتفاع الدم في النساء الحوامل.</p><p dir="RTL">حيث أن هيدروكلوروثيازيد ينفذ إلى لبن الثدي ، وقد يخمد</p><p dir="RTL">الإرضاع، فلا ينبغي استعماله في النساء</p><p dir="RTL">المرضعات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار على القدرة على القيادة وتشغيل الآلات</strong></p><p dir="RTL">قد يؤدي إزيدركس إلى ضعف ردود أفعال المريض ، ولا سيما</p><p dir="RTL">في بداية العلاج. لذلك يجب أن يُحذّر من هذا الأثر المرضى</p><p dir="RTL">الذين يقومون بقيادة المركبات أو تشغيل الآلات</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار المناوئة</strong></p><p dir="RTL"><strong>معدلات التكرار</strong></p><p dir="RTL">&raquo;شائع جداً &laquo; (&le; 1/10) ؛ &raquo;شائع &laquo; (&le; 1/100 إلى &gt; 1/10) ؛</p><p dir="RTL">&raquo;غير شائع &laquo; (&le; 1/1000 إلى &gt; 1/100) ؛ &raquo;نادراً &laquo; (&le; 1/100000</p><p dir="RTL">إلى &gt; 1/1000) ؛ &raquo;نادراً جداً &laquo; (&gt; 1/100000).</p><p dir="RTL"><strong>الدم</strong></p><p dir="RTL">نادراً: نقص الصفيحات ، أحيانا مع فرفرية.</p><p dir="RTL">نادرا جدا: نقص خلايا الدم البيضاء ، ندرة الخلايا الحبيبية ،</p><p dir="RTL">خمود النخاع العظمي ، أنيميا انحلالية.</p><p dir="RTL"><strong>الجهاز المناعي</strong></p><p dir="RTL">نادرا جداً: تفاعلات حساسية مفرطة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>اضطرابات الإلكتروليتات الأيض</strong></p><p dir="RTL">شائع: نقص بوتاسيوم الدم ولا سيما مع الجرعات العالية، ارتفاع</p><p dir="RTL">مستويات الدهون في الدم.</p><p dir="RTL">غير شائع: نقص صوديوم الدم ، نقص ماغنسيوم الدم ، زيادة</p><p dir="RTL">حمض البوليك في الدم.</p><p dir="RTL">نادرا: زيادة كالسيوم الدم ، زيادة جلوكوز الدم ، بيلة جلوكوزية،</p><p dir="RTL">تدهور الحالة الأيضية لمرض السكر.</p><p dir="RTL">نادراً جداً: قلوية الدم المصحوبة بنقص الكلور.</p><p dir="RTL"><strong>الجهاز العصبي</strong></p><p dir="RTL">نادراً: صداع، دوار أو خفة الرأس ، اضطرابات في النوم ، اكتئاب ،</p><p dir="RTL">تشوش الحس.</p><p dir="RTL"><strong>اضطرابات في العين</strong></p><p dir="RTL">اضطرابات بصرية، ولا سيما خلال الأسابيع القليلة الأولى من</p><p dir="RTL">العلاج.</p><p dir="RTL"><strong>انصباب المشيمية</strong></p><p dir="RTL">وقد سجل الأطباء حالات انصباب المشيمية مع خلل في المجال البصري</p><p dir="RTL">بعد استخدام مدرّات البول الثيازيدية والشبيهة بها ، وفي حال سجّل الأطباء</p><p dir="RTL">حالات تعاني من هذه المواد في المستقبل، فينبغي اتباع الإجراءات المناسبة</p><p dir="RTL">لتحديث معلومات المنتج بناءً عليها.</p><p dir="RTL"><strong>الجهاز القلبي الوعائي</strong></p><p dir="RTL">غير شائع: انخفاض وقوقي لضغط الدم . قد يتفاقم بواسطة</p><p dir="RTL">الكحول ، أو أدوية التخدير ، أو المهدئات.</p><p dir="RTL">نادراً: اضطرابات في النظم القلبي.</p><p dir="RTL"><strong>المسالك التنفسية</strong></p><p dir="RTL">نادرا جداً: أعراض تنفسية يشمل التهاب الرئة ووذمة رئوية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>القناة الهضمية</strong></p><p dir="RTL">غير شائع: فقدان الشهية، غثيان حفيف وقيء.</p><p dir="RTL">نادراًا: أعراض بطنية ، إمساك ، إسهال ، وأعراض مختصة بالقناة</p><p dir="RTL">الهضمية.</p><p dir="RTL">نادرا جداً: التهاب البنكرياس.</p><p dir="RTL"><strong>الكبد</strong></p><p dir="RTL">نادراً: ركود صفراوي داخل الكبد أو يرقان.</p><p dir="RTL"><strong>ال جلد</strong></p><p dir="RTL">غير شائع: شرى (ارتكاريا) وأشكال أخرى من الطفح، تشمل</p><p dir="RTL">الحمامي ، أحيانا مصحوب بحكة.</p><p dir="RTL">نادراً: تحسس ضوئية.</p><p dir="RTL">نادرا جداً: إلتهاب وعائي ناخر ، انحلال جلدي سمي ، تفاعلات</p><p dir="RTL">شبيهة بالذأب الحمامي ، إعادة تنشيط الذأب الحمامي الجلدي.</p><p dir="RTL"><strong>الجهاز التناسلي</strong></p><p dir="RTL">غير شائع: عنة.</p><p dir="RTL"><strong>الآثار الضارة بعد التسويق</strong></p><p dir="RTL">تم تحديد الآثار الضارة التالية بناءً على تجربة ما بعد التسويق. لأنه قد</p><p dir="RTL">تم الإبلاغ عن هذه الآثار طواعية من قطاع غير محدد من السكان، من غير</p><p dir="RTL">الممكن دائمًا تقدير وتيرة حدوثها بشكل موثوق.</p><p dir="RTL">وتيرتها غير معروفة:</p><p dir="RTL"><u>سرطان الجلد غير الميلانيني</u> (<u>سرطان الخلايا القاعدية وسرطان الخلايا</u></p><p dir="RTL"><u>الحرشفية</u>). شرح بعض ردود الفعل السلبية المختارة سرطان الجلد غير</p><p dir="RTL">الملانيني: بناءً على البيانات المتاحة من الدراسات الوبائية، تلاحظ وجود</p><p dir="RTL">علاقة معتمدة على الجرعة التراكمية بين هيدروكلوروثيازيدHCTZ وسرطان</p><p dir="RTL">الجلد غير الملانيني NMSC</p><p dir="RTL">(انظر قسمي &quot; التحذيرات والاحتياطات&quot; و &quot;الخصائص /الإجراءات&quot;)</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>يرجى الإبلاغ عن التأثيرات الدوائية الضارة إلى :</u></p><p dir="RTL">المركز الوطني للتيقظ والسلامة الدوائية (NPC):</p><p dir="RTL">فاكس: 7662-205-11-966+</p><p dir="RTL">مركز اتصال الهيئة العامة للغذاء والدواء : 19999</p><p dir="RTL">البريد الإلكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">الموقع الإلكتروني: https://ade.sfda.gov.sa</p><p dir="RTL"><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يُحفظ في العبوة الأصلية بعيدًا عن الرطوبة.</p><p>يُحفظ في العلبة الأصلية بعيدًا عن الضوء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>التركيب</strong></p><p dir="RTL"><em>المادة الفعالة</em>: هيدروكلوروثيازيد</p><p dir="RTL"><em>السواغ</em>: سواغ لعمل أقراص</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الشكل الصيدلاني وكمية المادة الفعالة في كل وحدة</strong></p><p dir="RTL">أقراص محززة بها 25 مجم</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>قرص مسجل.<br />يمكن تقسيم القرص إلى جرعتين متساويتين.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>مصنع:&nbsp;</p><p dir="RTL"><strong>سينيكسي </strong><strong>Cenexi</strong></p><p dir="RTL">فونتيناي سو بوا، فرنسا</p><p dir="RTL">مالك حق التسويق:&nbsp;</p><p dir="RTL">مختبرات جيفيسي فارماسيوتيكال</p><p dir="RTL">فيلربان- فرنسا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            مارس ٢٠٢١
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                ESIDREX 25 mg, scored tablet
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hydrochlorothiazide ....................................................................................................................... 25 mg
For one scored tablet.
Excipient(s) with known effect: Each tablet contains 50 mg of lactose and 49 mg of wheat starch For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Scored tablet.
The tablet can be divided into two equal half-doses.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Oedema due to heart or renal disease.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Oedema due to hepatic impairment usually in combination with a potassium-sparing diuretic.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Arterial hypertension</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p>As with all other diuretics, therapy should be initiated with the lowest possible dose. This dose should be established according to the individual patient&rsquo;s response to gain maximum therapeutic benefit while keeping side effects to a minimum. The daily dosage of ESIDREX can be administered as a single dose or in two divided doses, with or without food.</p><p><em><u>Oedemas</u></em></p><p>The starting dose is 50 to 100 mg/day, eventually 200 mg/day. The lowest effective dose should be identified by titration and be administered only during limited periods.</p><p>The maintenance dose is 25 to 50 mg/day or once every 2 days.</p><p><em><u>Hypertension</u></em></p><p>The current recommended dosages for high blood pressure are 12.5 or 25 mg/day.</p><p>For a given dose, the maximum effect is reached in 3 to 4 weeks. If the decrease in blood pressure proves inadequate with 25mg/day, combined treatment with another antihypertensive drug is recommended. Sodium and/or volume depletion should be corrected prior to the use of ESIDREX in combination with an ACE inhibitor, an angiotensin II receptor blocker or a direct renin inhibitor. Or the treatment should start under close medical supervision.</p><p><u>Specific populations</u></p><p><em><u>Renal impairment</u></em></p><p>Patients with mild to moderate renal impairment require no adjustment of the initial dose (see section 5.2).</p><p>ESIDREX is contraindicated in patients with anuria and with severe renal disease.</p><p><em><u>Hepatic impairment</u></em></p><p>&nbsp;</p><p>Patients with mild to moderate hepatic impairment require no adjustment of the initial dose.</p><p>ESIDREX should be used with particular caution in patients with severe hepatic impairment (see section 4.4).</p><p><u>Method of administration</u></p><p>This drug is administered orally.</p><p>The scored tablets should be taken with water.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                This drug should not be used in case of:
•	known hypersensitivity to hydrochlorothiazide or to any of the excipients listed in Section 6.1.
•	anuria,
•	severe renal disease (creatinine clearance lower than 30 ml/min).

This medicine is contraindicated in patients with a wheat allergy (other than coeliac disease).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Special warnings</u></p><p>Patients with bilateral renal artery stenosis, unilateral stenosis with a single functional kidney, or with hypokalaemia, should not normally take this medicinal product.</p><p>Hydrochlorothiazide is a sulfonamide. The possibility of an allergic cross-reaction with other sulfonamides, including antimicrobials, remains hypothetical and has not been validated clinically.</p><p><em><u>Hepatic impairment</u></em></p><p>Thiazide diuretics, like other diuretics, may precipitate electrolyte imbalance, hepatic encephalopathy or hepatorenal syndrome when used to treat cirrhotic ascites. Hydrochlorothiazide should be used with caution, especially in patients with severe hepatic impairment.</p><p><em><u>Non-melanoma skin cancer</u></em></p><p>An increased risk of non-melanoma skin cancer (NMSC) (basal cell carcinoma (BCC) and squamous cell carcinoma (SCC)) with an increase in the cumulative dose of hydrochlorothiazide (HCTZ) was observed in two epidemiological studies from the Danish Cancer Registry. The photosensitising effect of HCTZ could be a potential molecular mechanism of NMSC.</p><p>Patients taking HCTZ should be informed of the risk of NMSC and be advised to regularly check their skin for any new lesions and promptly report any suspicious skin damage. Preventative measures include limited exposure to the sun and UV rays and, if exposed, patients should be advised about adequate protection to minimise the risk of skin cancer. Suspicious skin damage should be examined as soon as possible, including potential histological analysis of biopsies. The use of HCTZ may also need to be reconsidered in patients who have previously been diagnosed with NMSC (see also section 4.8).</p><p>Photosensitive reactions have been reported during the use of thiazide diuretics (see section 4.8).</p><p>If a photosensitive reaction occurs during treatment, it is recommended that the treatment be discontinued. If re-administration of the treatment is essential, areas of the body exposed to the sun or artificial UVA should be protected.</p><p>This drug can be used by patients with coeliac disease. Wheat starch may contain gluten, but only trace amounts, and is therefore considered safe for patients with coeliac disease.</p><p>This drug contains lactose. Patients with a galactose intolerance, Lapp lactase deficiency or glucose- galactose malabsorption syndrome (rare hereditary diseases) are advised against taking this drug.</p><p>&nbsp;</p><p><u>Choroidal effusion, acute myopia and secondary angle-closure glaucoma:</u></p><p>Sulfonamide or sulfonamide derivative drugs can cause an idiosyncratic reaction resulting in <u>choroidal effusion with visual field defect</u>, transient myopia and acute angle-closure glaucoma. Symptoms include acute onset of decreased visual acuity or ocular pain and typically occur within hours to weeks of drug</p><p>&nbsp;</p><p>initiation. Untreated acute angle-closure glaucoma can lead to permanent vision loss. The primary treatment is to discontinue drug intake as rapidly as possible. Prompt medical or surgical treatments may need to be considered if the intraocular pressure remains uncontrolled. Risk factors for developing acute angle-closure glaucoma may include a history of sulfonamide or penicillin allergy.</p><p><u>Precautions for use </u>Electrolyte balance <em><u>Natraemia</u></em></p><p>Serum sodium concentration should be checked before treatment is initiated, and at regular intervals thereafter.</p><p>Thiazide diuretics can precipitate hyponatraemia or exacerbate pre-existing hyponatraemia. In severely sodium depleted and/ or volume-depleted patients, such as those receiving high doses of diuretics, symptomatic hypotension may occur in rare cases after initiation of treatment with hydrochlorothiazide.</p><p>As the drop in serum sodium may initially be asymptomatic, regular monitoring is essential and should be even more frequent in at-risk populations: elderly subjects, particularly those with malnutrition, and patients with cirrhosis (see sections 4.8 and 4.9).</p><p>Patients with ascites due to liver cirrhosis and patients with oedema caused by nephrotic syndrome must be monitored particularly closely.</p><p>Hyponatraemia, accompanied by neurological symptoms (nausea, progressive disorientation, apathy) has been observed in isolated cases. Thiazide diuretics should only be used after correction of any pre- existing sodium and/or volume depletion. Otherwise, treatment should be started under close medical supervision.</p><p><em><u>Kalaemia</u></em></p><p>Thiazide and related diuretics may precipitate new-onset hypokalaemia or exacerbate pre-existing hypokalaemia. Thiazide diuretics should be administered with caution in patients with conditions involving significant loss of potassium, for example, in salt-losing nephropathies or prerenal (cardiogenic) impairment of kidney function.</p><p>The risk of onset of hypokalaemia (&lt;3.5 mmol/L) must be considered in certain at-risk populations: elderly and/or malnourished and/or polymedicated subjects, cirrhosis patients with oedema and ascites, and patients with coronary heart disease or heart failure. This is because, in these patients, hypokalaemia increases the cardiac toxicity of digitalis glycosides and the risk of heart rhythm disorders.</p><p>Patients with a prolonged QT interval on ECG are also at risk, whether this is congenital or drug-induced. Hypokalaemia (like bradycardia) predisposes such patients to the onset of severe heart rhythm disorders, notably torsades de pointes, which can be fatal, particularly in the presence of bradycardia.</p><p>Correction of hypokalaemia and any coexisting hypomagnesaemia is recommended prior to the initiation of thiazides.</p><p>The first plasma potassium measurement must be taken in the week after the treatment is introduced.</p><p>Thereafter, serum potassium concentrations should be carried out periodically. All patients receiving thiazide diuretics should be monitored for imbalances in electrolytes, particularly potassium.</p><p>For chronic treatment, serum potassium concentrations should be checked at the start of treatment. Monitoring at weeks 3-4 may be considered depending on the risk factors. Regular monitoring is subsequently advised, particularly in at-risk patients.</p><p><em><u>Uric acid</u></em></p><p>Like other diuretics, ESIDREX can produce an increase in plasma concentrations of uric acid, due to the decrease in its urinary excretion, and thus contribute to the onset of hyperuricaemia or exacerbate pre-existing hyperuricaemia, potentially triggering episodes of gout in predisposed patients.</p><p>The dose must be adapted based on plasma concentrations of uric acid.</p><p>&nbsp;</p><p>Metabolic effects</p><p><em><u>Serum calcium</u></em></p><p>Thiazide diuretics decrease urinary excretion of calcium and can result in a mild, temporary elevation in serum calcium in patients with no known calcium metabolism problems. ESIDREX must be used with caution in patients with hypercalcaemia and must not be administered until after any pre-existing hypercalcaemia has been corrected. ESIDREX must be withdrawn if patients develop hypercalcaemia during treatment. Serum calcium must be monitored regularly during treatment with thiazide diuretics. Marked hypercalcaemia may indicate hidden hyperparathyroidism. Thiazide diuretics must be withdrawn before investigating parathyroid function.</p><p><em><u>Blood glucose and serum lipids</u></em></p><p>Thiazide diuretics, including hydrochlorothiazide, may decrease glucose tolerance and raise serum levels of cholesterol and triglyceride. Patients with diabetes may require adaptation of their doses of insulin or oral glucose-lowering agents.</p><p><em><u>Renal function and diuretics</u></em></p><p>Thiazide diuretics are fully effective only in patients with normal or mildly impaired renal function (assessed for example by calculating creatinine clearance from serum creatinine level). In elderly subjects, creatinine clearance values must be adjusted based on the age, weight and sex of the patient, using the Cockcroft-Gault formula, for example:</p><p>CrCl = (140 - age) x weight/0.814 x serum creatinine With:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; age expressed in years,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; weight in kg,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; serum creatinine in micromol/L.</p><p>&nbsp;</p><p>This formula is valid for elderly male subjects, and must be corrected for women by multiplying the result by 0.85.</p><p>The hypovolaemia, secondary to the loss of water and sodium, induced by the diuretic at the start of treatment, leads to a reduction in glomerular filtration rate. This may result in an increase in blood urea and serum creatinine.</p><p>This temporary functional renal impairment may exacerbate pre-existing renal impairment.</p><p><em><u>Acute myopia and secondary angle-closure glaucoma</u></em></p><p>Hydrochlorothiazide, a sulfonamide, has been associated with an idiosyncratic reaction resulting in acute transient myopia and acute angle-closure glaucoma. Symptoms include acute onset of decreased visual acuity or ocular pain and typically occur within hours to weeks of drug initiation. Untreated acute angle-closure glaucoma can lead to permanent vision loss. The primary treatment is to discontinue hydrochlorothiazide as rapidly as possible. Risk factors for developing acute angle-closure glaucoma may include a history of sulfonamides or penicillin allergy.</p><p>Others</p><p><em><u>Combinations with anti-hypertensives</u></em></p><p>It is advisable to reduce the dose when used in combination with another antihypertensive, at least initially.</p><p>The anti-hypertensive effect of ACE inhibitors, angiotensin II antagonists or renin inhibitors is potentiated by treatments that increase plasma renin activity (diuretics).</p><p>Caution is advised when an ACE inhibitor, an angiotensin II antagonist, or a direct renin inhibitors is co- administered with ESIDREX, particularly in severely sodium-depleted and/or volume depleted patients.</p><p><em><u>Athletes</u></em></p><p>Athletes must be made aware that this product contains an active substance that may produce a positive reaction in an anti-doping test.</p><p><em><u>Other</u></em></p><p>Lupus erythematosus: cases of exacerbation or activation of systemic lupus erythematosus have been reported with thiazide diuretics, including hydrochlorothiazide.</p><p>Hypersensitivity reactions to hydrochlorothiazide are more likely in patients with allergy and asthma.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Interactions may result from concomitant administration of ESIDREX with the following medicinal products.</p><p>+ Potassium-lowering medicinal products</p><p>Hypokalaemia is a contributing factor to the onset of heart rhythm disorders (notably torsades de pointes) and the increased toxicity of certain medicinal products, such as digoxin. As such, medicinal products that can result in hypokalemia are involved in a large number of interactions. These consist of potassium-lowering diuretics, used alone or in combination, stimulant laxatives, glucocorticoids, tetracosactide and amphotericin B (IV administration).</p><p>+ Sodium-lowering medicinal products</p><p>Certain medicinal products are more commonly involved in the onset of hyponatraemia. These consist of diuretics, desmopressin, selective serotonin reuptake inhibitor antidepressants, carbamazepine and oxcarbazepine. Using these medicinal products in combination increases the risk of hyponatraemia.</p><p><u>Combinations to avoid</u></p><p><strong>+ Lithium</strong></p><p>Increased serum lithium with signs of lithium overdose, such as with a low sodium diet (decreased renal excretion of lithium).</p><p>If the combination cannot be avoided, carefully monitor serum lithium and adapt the lithium dose.</p><p><u>Combinations subject toprecautions for use</u></p><p><strong>+ Acetylsalicylic acid</strong></p><p>When using acetylsalicylic acid as an anti-inflammatory (&ge; 1 g per dose and/or &ge; 3 g per day) or for pain relief or to treat fever (&ge; 500 mg per dose and/or &lt; 3 g per day):</p><p>Acute kidney injury in patients with dehydration, due to reduced glomerular filtration rate secondary to reduced renal prostaglandin synthesis. The antihypertensive effect is also reduced.</p><p>Hydrate the patient and monitor renal function at the start of treatment.</p><p>+ Nonsteroidal anti-inflammatories</p><p>Acute kidney injury in at-risk (elderly and/or dehydrated) patients due to reduced glomerular filtration rate (inhibition of prostaglandin-mediated vasodilation by nonsteroidal anti-inflammatories). The antihypertensive effect is also reduced.</p><p>Hydrate the patient and monitor renal function at the start of treatment.</p><p>+ Carbamazepine</p><p>Risk of symptomatic hyponatraemia. Clinical and laboratory monitoring required. If possible, use a different class of diuretics.</p><p>+ Ion-exchange resins</p><p>Taking ion-exchange resins can reduce the intestinal absorption and, potentially, efficacy of other medicinal products taken concomitantly. Ion-exchange resins should generally be taken separately from other medicinal products, with an interval of more than 2 hours between them if possible.</p><p>+ Digitalis glycosides</p><p>Hypokalaemia predisposing patients to the toxic effects of digitalis glycosides.</p><p>Correct any hypokalaemia before starting treatment, and put the patient on clinical, electrolyte and electrocardiogram monitoring.</p><p>+ Potassium-sparing diuretics (alone or in combination)</p><p>&nbsp;</p><p>Although the logical combination is useful for some patients, the onset of hypokalaemia or hyperkalaemia, particularly in patients with renal impairment or diabetes, cannot be ruled out.</p><p>Monitor serum potassium, with ECG if necessary, and reconsider the treatment if required.</p><p>&nbsp;</p><p>+ Angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers</p><p>Risk of sudden hypotension and/or acute kidney injury when introducing or increasing the dose of treatment with an angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker in patients with pre-existing salt and water depletion.</p><p>In patients with hypertension for whom previous diuretic treatment resulted in salt and water depletion, it is necessary to:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; either withdraw the diuretic before beginning treatment with the angiotensin II receptor blocker or ACE inhibitor, and reintroduce a potassium-lowering diuretic if subsequently required;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; or administer a reduced dose of the angiotensin II receptor blocker or ACE inhibitor to begin with and gradually increase the dose.</p><p>In patients with congestive heart failure on diuretic therapy, begin the ACE inhibitor or angiotensin II receptor blocker on a very low dose, if needed after reducing the dose of the potassium-lowering diuretic used in combination.</p><p>In all cases, monitor renal function (serum creatinine) in the first few weeks of treatment with an ACE inhibitor or angiotensin II receptor blocker</p><p><strong>+ Medicinal products that may cause torsades de pointes </strong>(amiodarone, amisulpride, arsenic-based agents, artenimol, chloroquine, chlorpromazine, citalopram, cyamemazine, diphemanil, disopyramide, dofetilide, dolasetron, domperidone, dronedarone, droperidol, erythromycin, escitalopram, flupentixol, fluphenazine, halofantrine, haloperidol, hydroquinidine, hydroxyzine, ibutilide, levofloxacin, levomepromazine, lumefantrine, mequitazine, methadone, mizolastine, moxifloxacin, pentamidine, pimozide, pipamperone, piperaquine, pipotiazine, prucalopride, quinidine, sotalol, spiramycin, sulpiride, sultopride, tiapride, toremifene, vandetanib, vincamine, zuclopenthixol)</p><p>Increased risk of ventricular arrhythmias, particularly torsades de pointes.</p><p>Correct any hypokalaemia before administering the product and put the patient on clinical, electrolyte and electrocardiogram monitoring.</p><p>+ Other potassium-lowering agents</p><p>Increased risk of hypokalaemia. Monitor serum potassium with correction if needed.</p><p>+ Iodinated contrast products</p><p>In patients with diuretic-induced dehydration, increased risk of functional acute kidney injury, particularly if iodinated contrast products are used at high doses.</p><p>Rehydrate before administering the iodinated contrast product.</p><p><u>Combinations to take into consideration</u></p><p><strong>+ Alpha-blockers for urological purposes (alfuzosin, doxazosin, prazosin, silodosin, tamsulosin, terazosin)</strong></p><p>Increased hypotensive effect. Increased risk of orthostatic hypotension.</p><p>+ Antihypertensive alpha-blockers</p><p>Increased hypotensive effect. Increased risk of orthostatic hypotension.</p><p>+ Medicinal products causing orthostatic hypotension</p><p>Other than antihypertensives, numerous medicinal products may cause orthostatic hypotension. They include in particular nitrovasodilators, phosphodiesterase type 5 inhibitors, alpha-blockers for urological purposes, tricyclic antidepressants and phenothiazine antipsychotics, dopamine agonists, levodopa, baclofen, amifostine, etc.</p><p>Increased risk of hypotension, in particular orthostatic hypotension.</p><p>+ Calcium</p><p>Risk of hypercalcaemia due to reduced urinary excretion of calcium.</p><p>&nbsp;</p><p>+ Ciclosporin</p><p>Risk of increased serum creatinine with no change in blood concentrations of ciclosporin, even in the absence of salt and water depletion. Also risk of hyperuricaemia and complications such as gout.</p><p>+ Nitrovasodilators and related products</p><p>Increased risk of hypotension, in particular orthostatic hypotension.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>There are limited data on the use of hydrochlorothiazide during pregnancy, particularly during the first trimester. The animal studies are inadequate.</p><p>Hydrochlorothiazide crosses the placenta. Based on the pharmacological mechanism of action of hydrochlorothiazide, using it during the second and third trimesters of pregnancy may reduce foetoplacental circulation and produce fetal and neonatal effects such as jaundice, electrolyte imbalance and thrombocytopenia.</p><p>Hydrochlorothiazide must not be used in patients with gestational oedema, gestational hypertension or pre-eclampsia due to the risk of reduced plasma volume and placental hypoperfusion, with no beneficial effect on the disease course.</p><p>Hydrochlorothiazide must not be used to treat essential hypertension in pregnant women, other than in exceptional cases where no other treatment can be used.</p><p><u>Breastfeeding</u></p><p>Hydrochlorothiazide is excreted in human milk in low quantities. High-dose thiazide diuretics resulting in significant urine output may inhibit lactation.</p><p>The use of ESIDREX in breast-feeding women is not recommended. If ESIDREX is used in breast- feeding women, this must remain at the lowest possible dose.</p><p><u>Fertility</u></p><p>There are no human fertility data for ESIDREX.</p><p>In animal studies, hydrochlorothiazide had no effect on fertility and conception (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not relevant.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Adverse reactions (Table 1) are ranked by frequency, starting with the most frequent according to the following convention: very common (&gt;1/10); common (&gt;1/100, &lt;1/10); uncommon (&gt;1/1000, &lt;1/100); rare (&gt;1/10000, &lt;1/1000); very rare (&lt;1/10000) and unknown (cannot be estimated based on available data).</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Thrombocytopenia sometimes with purpura</p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Bone&nbsp;&nbsp;&nbsp; marrow&nbsp;&nbsp;&nbsp; failure,&nbsp;&nbsp;&nbsp; haemolytic&nbsp;&nbsp;&nbsp; anaemia, leukopoenia, agranulocytosis</p></td></tr><tr><td style="vertical-align:top"><p>Frequency unknown</p></td><td style="vertical-align:top"><p>Aplastic anaemia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Hypersensitivity reaction</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very frequent</p></td><td style="vertical-align:top"><p>Hypokalaemia, blood lipids increased</p></td></tr><tr><td style="vertical-align:top"><p>Frequent</p></td><td style="vertical-align:top"><p>Hyperuricaemia,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hypomagnesaemia, hyponatraemia</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Hypercalcaemia,&nbsp;&nbsp;&nbsp; hyperglycaemia,&nbsp;&nbsp;&nbsp; glycosuria, worsening of diabetic metabolic state</p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Hypochloraemic alkalosis</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Psychiatric disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Depression, sleep disorders</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Headache, dizziness, paraesthesia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Eye disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Visual impairment</p></td></tr><tr><td style="vertical-align:top"><p>Unknown frequency</p></td><td style="vertical-align:top"><p>Acute&nbsp;&nbsp;&nbsp;&nbsp; angle-closure&nbsp;&nbsp;&nbsp;&nbsp; glaucoma,&nbsp;&nbsp;&nbsp;&nbsp; Choroidal effusion**</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Cardiac disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Arrhythmias</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Frequent</p></td><td style="vertical-align:top"><p>Orthostatic hypotension</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Respiratory distress (including pneumonia and pulmonary oedema)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Gastro-intestinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Frequent</p></td><td style="vertical-align:top"><p>Diarrhoea, decreased appetite, nausea and vomiting</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Abdominal discomfort, constipation</p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Pancreatitis</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Hepatobiliary disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Intrahepatic cholestasis, jaundice</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Skin and sub-cutaneous tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Frequent</p></td><td style="vertical-align:top"><p>Urticaria and other forms of rash</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Photosensitive reaction</p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Necrotizing vasculitis and toxic epidermal necrolysis, cutaneous lupus erythematosus like reactions, reactivation of cutaneous lupus erythematosus.</p></td></tr><tr><td style="vertical-align:top"><p>Unknown frequency</p></td><td style="vertical-align:top"><p>Erythema multiforme</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Unknown frequency</p></td><td style="vertical-align:top"><p>Muscle spasm</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Renal and urinary disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Acute renal failure</p></td></tr><tr><td style="vertical-align:top"><p>Unknown frequency</p></td><td style="vertical-align:top"><p>Renal disorder</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Reproductive system and breast disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Frequent</p></td><td style="vertical-align:top"><p>Impotence</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>General disorders and administration site reactions</strong></p></td></tr><tr><td style="vertical-align:top"><p>Unknown frequency</p></td><td style="vertical-align:top"><p>Asthenia, fever</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Benign, malignant and unspecified tumours (including cysts and polyps)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Unknown frequency</p></td><td style="vertical-align:top"><p>Non-melanoma&nbsp;&nbsp;&nbsp;&nbsp; skin&nbsp;&nbsp;&nbsp;&nbsp; cancer*&nbsp;&nbsp;&nbsp;&nbsp; (basal&nbsp;&nbsp;&nbsp;&nbsp; cell carcinoma and squamous cell carcinoma)</p></td></tr></tbody></table><p>&nbsp;</p><p><em>*Based on available data from epidemiological studies, a dose-dependent cumulative association between HCTZ and NMSC has been observed (see also sections 4.4 and 5.1).</em></p><p><em>**Cases of choroidal effusion with visual field defect have been reported after the use of thiazide</em></p><p><em>and thiazide-like diuretics. If cases are to be reported for these substances in the future, the appropriate procedure should be used to update the product information accordingly.</em></p><p><u>Reporting of suspected adverse reactions</u></p><p>It is important to declare any suspected adverse effects after drug authorization. This ensures ongoing monitoring of the drug&rsquo;s risk/benefit ratio. Healthcare professionals should report any suspected adverse reactions via the national reporting system: Please report adverse drug events to:</p><p>The National Pharmacovigilance Centre (NPC):</p><p>Fax: +966-11-205-7662</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Hydrochlorothiazide overdose is associated with electrolyte depletion (hypokalaemia, hypochloraemia, hyponatraemia) and dehydration due to excessive urination. The most common signs and symptoms of overdose are nausea and drowsiness. Hypokalaemia can cause muscle spasms and/or exacerbate the cardiac arrhythmias associated with concomitant use of digitalis glucosides and some antiarrhythmic medicinal products.</p><p>Treatment consists of restoring the water-electrolyte balance, hyponatraemia must be corrected gradually. Cardiovascular monitoring should be put in place depending on the patient&rsquo;s clinical status.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic class: CORTICAL DILUTING SEGMENT DIURETICS ATC code: C03AA03.</p><p><strong><u>Mechanism of action</u></strong></p><p>Hydrochlorothiazide, the active substance in ESIDREX is a benzothiadiazide diuretic.</p><p>Thiazide diuretics act primarily on the distal renal tubule (early convoluted part), inhibiting the reabsorption of sodium chloride (by blocking the NaCl cotransporter).</p><p>The enhanced delivery of Na+ and water to the cortical collecting tubule and/or the increased flow rate leads to increased secretion and excretion of K+ and H+. The inhibition of NaCl reabsorption also results in indirect stimulation of Ca2+reabsorption.</p><p>The diuretic and natriuretic effect appears within 1 to 2 hours after oral administration of hydrochlorothiazide.</p><p>Maximum activity is reached after 4 to 6 hours and may persist for 10 to 12 hours.</p><p>Thiazide-induced diuresis initially leads to decreases in plasma volume, cardiac output, and systemic blood pressure. The renin-angiotensin-aldosterone system may become activated. With continuous administration, the hypotensive effect is maintained, probably due to a fall in total peripheral vascular resistance; cardiac output returns to pre-treatment values, plasma volume remains somewhat reduced, and plasma renin activity may be elevated.</p><p><u>Hypertension</u></p><p>With chronic administration, the anti-hypertensive effect of ESIDREX is dose dependent in most patients, for doses ranging from 12.5 mg/day up to 50-75 mg/day.</p><p>The therapeutic effect of thiazide diuretics plateaus beyond a certain dose, while the undesirable effects continue to increase: if the treatment is ineffective, increasing the dose beyond the recommended posology is of no benefit, and is often poorly tolerated (see section 4.2).</p><p>In patients with nephrogenic diabetes insipidus, hydrochlorothiazide reduces urinary volume and increases urinary osmolality.</p><p><u>Non-melanoma skin cancer</u></p><p>Based on available data from epidemiological studies, a dose-dependent cumulative association between HCTZ and NMSC has been observed.</p><p>One trial included a population of 71,533 cases of BCC and 8,629 cases of SCC matched to 1,430,833 and 172,462 controls in the population, respectively. High use of HCTZ (cumulative dose &ge;50,000 mg) was associated with an adjusted odds ratio (OR) of 1.29 (95% confidence interval: 1.23-1.35) for BCC and 3.98 (95% confidence interval: 3.68-4.31) for SCC. A clear relationship between the cumulative dose-response relationship was observed for BCC and SCC.</p><p>Another trial showed a possible association between lip cancer (SCC) and exposure to HCTZ: 633 cases of lip cancer were matched to 63,067 controls in the population, using a risk-based sampling strategy. A cumulative dose-response relationship has&nbsp; been demonstrated with an adjusted OR&nbsp; of&nbsp; 2.1&nbsp;&nbsp; &nbsp;(95%</p><p>&nbsp;</p><p>confidence interval: 1.7-2.6) up to an OR of 3.9 (3.0-4.9) for high use (~25000 mg) and an OR of 7.7 (5.7-10.5) for the highest cumulative dose (~100,000 mg) (see also section 4.4).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>Following oral administration, hydrochlorothiazide is rapidly absorbed (Tmax of around 2 hours). The increase in mean AUC is linear and dose-proportional within the therapeutic window.</p><p>Food intake has a limited clinical impact on absorption of hydrochlorothiazide. Following oral administration, the absolute bioavailability of hydrochlorothiazide is 70%.</p><p>In patients with congestive heart failure, absorption of hydrochlorothiazide is reduced.</p><p>Continuous administration does not affect the metabolism of hydrochlorothiazide. After 3 months of treatment with a daily dose of 50 mg of hydrochlorothiazide, absorption, elimination or excretion are similar to what is observed during short-term treatments.</p><p><u>Distribution</u></p><p>Hydrochlorothiazide accumulates in erythrocytes, reaching a peak concentration 4 hours after oral administration. After 10 hours, the concentration in erythrocytes is approximately 3 times higher than that of plasma. Binding to plasma proteins to the extent of approximately 40-70% has been reported, and the apparent volume of distribution has been estimated at 4-8 L/kg.</p><p>The half-life varies significantly from one subject to another: it is between 6 and 25 hours.</p><p><u>Elimination</u></p><p>Hydrochlorothiazide is largely unchanged when it leaves the plasma, with a half-life of approximately 6 to 15 h in the terminal elimination phase. Within 72 hours, 60 to 80% of a single oral dose is excreted in the urine, 95% in unchanged form, and 4% as 2-amino-4-chloro-m-benzenedisulfonamide hydrolyzate (ABCS). Up to 24% of an oral dose is found in faeces and a negligible amount is excreted in the bile.</p><p>In patients with renal impairment or heart failure, the renal clearance of hydrochlorothiazide is reduced, and its elimination half-life is increased. This is also the case in elderly subjects, in whom an increase in the maximum plasma concentration is also observed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The mutagenic potential was assessed in a series of in vitro and in vivo test systems. While some positive results were obtained in vitro, all in vivo tests were negative.</p><p>Hydrochlorothiazide showed no carcinogenic activity in rats. In mice, hepatocellular carcinoma was observed in males receiving a high dose with an incidence not greater than that usually seen in the control animals.</p><p>Hydrochlorothiazide is not teratogenic and has no effects on fertility and conception. No teratogenic potential was revealed in 3 animal species receiving doses at least 10 times higher than the recommended human doses, of the order of 1 mg/kg. A decrease in weight gain in suckling rat pups was attributed to the high dose (15 times the human dose) and diuretic effects of hydrochlorothiazide, with subsequent effects on milk production (see section 4.6).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Lactose monohydrate, wheat starch, talc, colloidal anhydrous silica, magnesium stearate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not relevant.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in the original package away from moisture.</p><p>Store in the original package away from light.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>20 scored tablets within blisters (PVC/PE/PVDC/Aluminium).</p><p>30 scored tablets within blisters (PVC/PE/PVDC/Aluminium).</p><p>90 scored tablets within blisters (PVC/PE/PVDC/Aluminium).</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No specific requirements</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                LABORATOIRES JUVISE PHARMACEUTICALS
149 BOULEVARD BATAILLE DE STALINGRAD
69100 VILLEURBANNE

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                March 2021
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>